C. Kramer Robin's Insider Trades & SAST Disclosures
C. Kramer Robin's most recent trade in Biogen Inc was a trade of 834 Common Stock done . Disclosure was reported to the exchange on Feb. 10, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern C. Kramer Robin.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2025 | 834 | 8,256 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2025 | 834 | 0 | - | - | Restricted Stock Unit | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 142.54 per share. | 10 Feb 2025 | 245 | 8,011 (0%) | 0% | 142.5 | 34,922 | Common Stock |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 10,535 | 10,535 | - | - | Restricted Stock Unit | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 788 | 7,195 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 788 | 789 | - | - | Restricted Stock Unit | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 703 | 7,666 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 703 | 1,407 | - | - | Restricted Stock Unit | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 141.35 per share. | 06 Feb 2025 | 244 | 7,422 (0%) | 0% | 141.3 | 34,489 | Common Stock |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 141.35 per share. | 06 Feb 2025 | 232 | 6,963 (0%) | 0% | 141.3 | 32,793 | Common Stock |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Dec 2024 | 351 | 6,577 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Dec 2024 | 351 | 0 | - | - | Restricted Stock Unit | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.78 per share. | 06 Dec 2024 | 170 | 6,407 (0%) | 0% | 157.8 | 26,823 | Common Stock |
| Biogen Inc | Kramer C. Robin | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 914 | 6,191 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Kramer C. Robin | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 914 | 0 | - | - | Performance Stock Unit | |
| Biogen Inc | C. Robin Kramer | Chief Accounting Officer | Other type of transaction at price $ 0.00 per share. | 16 Feb 2024 | 537 | 0 | - | - | Restricted Stock Unit | |
| Biogen Inc | Kramer C. Robin | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 431 | 537 | - | - | Restricted Stock Unit | |
| Biogen Inc | Robin Kramer C. | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 431 | 6,353 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | C. Robin Kramer | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 219.08 per share. | 16 Feb 2024 | 269 | 5,922 (0%) | 0% | 219.1 | 58,933 | Common Stock |
| Biogen Inc | Robin Kramer C. | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 219.08 per share. | 16 Feb 2024 | 127 | 6,226 (0%) | 0% | 219.1 | 27,823 | Common Stock |
| Biogen Inc | C. Robin Kramer | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 833 | 5,522 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 833 | 834 | - | - | Restricted Stock Unit | |
| Biogen Inc | Robin Kramer C. | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 240.98 per share. | 09 Feb 2024 | 245 | 5,277 (0%) | 0% | 241.0 | 59,040 | Common Stock |
| Biogen Inc | Kramer C. Robin | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 2,110 | 2,110 | - | - | Restricted Stock Unit | |
| Biogen Inc | C. Kramer Robin | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2024 | 788 | 4,942 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Kramer Robin C. | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2024 | 788 | 1,577 | - | - | Restricted Stock Unit | |
| Biogen Inc | Kramer Robin C. | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 240.30 per share. | 07 Feb 2024 | 253 | 4,689 (0%) | 0% | 240.3 | 60,796 | Common Stock |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2024 | 914 | 914 | - | - | Performance Stock Unit | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2023 | 351 | 351 | - | - | Restricted Stock Unit | |
| Biogen Inc | C. Kramer Robin | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2023 | 351 | 4,324 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Kramer Robin C. | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 239.29 per share. | 08 Dec 2023 | 170 | 4,154 (0%) | 0% | 239.3 | 40,679 | Common Stock |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2023 | 252 | 0 | - | - | Restricted Stock Unit | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2023 | 252 | 4,095 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 284.85 per share. | 30 Jun 2023 | 122 | 3,973 (0%) | 0% | 284.9 | 34,752 | Common Stock |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2023 | 512 | 1,422 | - | - | Restricted Stock Unit | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2023 | 512 | 3,843 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Other type of transaction at price $ 0.00 per share. | 17 Feb 2023 | 454 | 968 | - | - | Restricted Stock Unit | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 278.38 per share. | 17 Feb 2023 | 238 | 3,331 (0%) | 0% | 278.4 | 66,254 | Common Stock |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 833 | 3,931 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 833 | 1,667 | - | - | Restricted Stock Unit | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Other type of transaction at price $ 0.00 per share. | 10 Feb 2023 | 278 | 0 | - | - | Restricted Stock Unit | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 286.30 per share. | 10 Feb 2023 | 262 | 3,669 (0%) | 0% | 286.3 | 75,011 | Common Stock |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 286.30 per share. | 10 Feb 2023 | 261 | 3,569 (0%) | 0% | 286.3 | 74,724 | Common Stock |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 228 | 3,897 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 228 | 278 | - | - | Restricted Stock Unit | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 286.30 per share. | 10 Feb 2023 | 67 | 3,830 (0%) | 0% | 286.3 | 19,182 | Common Stock |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 2,365 | 2,365 | - | - | Restricted Stock Unit | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2023 | 887 | 3,098 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2022 | 350 | 702 | - | - | Restricted Stock Unit | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2022 | 350 | 2,367 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 289.10 per share. | 08 Dec 2022 | 156 | 2,211 (0%) | 0% | 289.1 | 45,100 | Common Stock |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2022 | 252 | 2,091 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2022 | 252 | 252 | - | - | Restricted Stock Unit | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 210.64 per share. | 01 Jul 2022 | 74 | 2,017 (0%) | 0% | 210.6 | 15,587 | Common Stock |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Other type of transaction at price $ 0.00 per share. | 18 Feb 2022 | 570 | 1,934 | - | - | Restricted Stock Unit | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 396 | 2,504 | - | - | Restricted Stock Unit | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2022 | 396 | 1,854 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 209.79 per share. | 18 Feb 2022 | 117 | 1,737 (0%) | 0% | 209.8 | 24,545 | Common Stock |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Other type of transaction at price $ 0.00 per share. | 12 Feb 2022 | 326 | 506 | - | - | Restricted Stock Unit | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Other type of transaction at price $ 0.00 per share. | 12 Feb 2022 | 189 | 0 | - | - | Restricted Stock Unit | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2022 | 176 | 832 | - | - | Restricted Stock Unit | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2022 | 176 | 1,594 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2022 | 99 | 1,453 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2022 | 99 | 189 | - | - | Restricted Stock Unit | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 214.59 per share. | 12 Feb 2022 | 85 | 1,458 (0%) | 0% | 214.6 | 18,240 | Common Stock |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 214.59 per share. | 12 Feb 2022 | 51 | 1,543 (0%) | 0% | 214.6 | 10,944 | Common Stock |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 214.60 per share. | 12 Feb 2022 | 35 | 1,418 (0%) | 0% | 214.6 | 7,511 | Common Stock |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 2,500 | 2,500 | - | - | Restricted Stock Unit | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2022 | 244 | 1,354 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2021 | 251 | 504 | - | - | Restricted Stock Unit | |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 348.92 per share. | 01 Jul 2021 | 251 | 945 (0%) | 0% | 348.9 | 87,579 | Common Stock |
| Biogen Inc | Robin C. Kramer | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 348.92 per share. | 01 Jul 2021 | 74 | 871 (0%) | 0% | 348.9 | 25,820 | Common Stock |
| Biogen Inc | Robin C. Kramer | SVP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2021 | 2,900 | 2,900 | - | - | Restricted Stock Unit | |
| Biogen Inc | Robin C. Kramer | SVP, Chief Accounting Officer | Other type of transaction at price $ 0.00 per share. | 12 Feb 2021 | 289 | 1,008 | - | - | Restricted Stock Unit | |
| Biogen Inc | Robin C. Kramer | SVP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 213 | 706 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Robin C. Kramer | SVP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 213 | 1,297 | - | - | Restricted Stock Unit | |
| Biogen Inc | Robin C. Kramer | SVP, Chief Accounting Officer | Other type of transaction at price $ 0.00 per share. | 12 Feb 2021 | 166 | 288 | - | - | Restricted Stock Unit | |
| Biogen Inc | Robin C. Kramer | SVP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 120 | 493 (0%) | 0% | 0 | Common Stock | |
| Biogen Inc | Robin C. Kramer | SVP, Chief Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 120 | 454 | - | - | Restricted Stock Unit | |
| Biogen Inc | Robin C. Kramer | SVP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 278.03 per share. | 12 Feb 2021 | 73 | 591 (0%) | 0% | 278.0 | 20,296 | Common Stock |
| Biogen Inc | Robin C. Kramer | SVP, Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 278.02 per share. | 12 Feb 2021 | 42 | 664 (0%) | 0% | 278.0 | 11,677 | Common Stock |
| Biogen Inc | Robin C. Kramer | VP, Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2020 | 755 | 755 | - | - | Restricted Stock Unit |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges